Abstract: gd T cells represent a minor T-cell subset that is mainly distributed in mucosal surfaces. Two distinct lymphomas derived from these cells have been recognized: hepatosplenic gd T-cell lymphoma (HSTL) and primary cutaneous gd T-cell lymphoma (PCGD-TCL). However, whether other anatomic sites may also be involved and whether they represent a spectrum of the same disease are not well studied. The lack of T-cell receptor (TCR)b expression has been used to infer a gd origin when other methods are not available. We studied 35 T-cell tumors suspected to be gd TCL using monoclonal antibodies reactive with TCR d or g in paraffin sections. We were able to confirm gd chain expression in 22 of 35 cases. We identified 8 PCGD-TCLs, 6 HSTLs, and 8 gd TCLs without hepatosplenic or cutaneous involvement involving mainly extranodal sites. Two such cases were classified as enteropathy-associated T-cell lymphoma, type II. The other gd TCL presented in the intestine, lung, tongue, orbit, and lymph node. In addition, we observed 13 cases with mainly extranodal involvement that lacked any TCR expression ("TCR silent"). In all cases, a natural killer cell origin was excluded. In conclusion, the lack of TCRb expression does not always predict gd-T-cell derivation, as TCR silent cases may be found. The recognition of gd TCL presenting in extranodal sites other than skin and liver/spleen expands the clinical spectrum of these tumors. However, non-HSTL gd TCL do not seem to represent a single entity. The relationship of these tumors with either HSTL or PCGD-TCL requires further study.
N ormal gd T cells comprise an immunologically distinct lymphoid population that corresponds to <1% to 5% of peripheral blood lymphocytes and up to 50% of T cells in mucosal sites, particularly the intestine and skin. 6, 7, 17, [22] [23] [24] gd T cells, along with natural killer (NK) cells, are components of the innate immune system and do not require specialized antigen processing and presentation. 4, 8 Furthermore, gd T-cells are involved in regulation of immune responses including cell recruitment and activation and tissue repair. 7, 16, 27 The 2008 World Health Organization (WHO) classification recognizes 2 main types of gd T-cell lymphoma (TCL), gd hepatosplenic T-cell lymphoma (HSTL) 5, 11 and primary cutaneous gd T-cell lymphoma (PCGD-TCL). 2, 12, 26, 35 Nevertheless, infrequent examples of gd TCL have been reported to present in mucosal sites. 2, 12, 26 The relationship of such lesions with the more common primary cutaneous gd T-cell tumors is unknown.
The investigation of gd TCLs is limited by the rarity of these tumors and by the absence of reliable methodologies Copyright r 2011 by Lippincott Williams & Wilkins to assess gd T-cell origin in routine diagnostic specimens. In this study, we describe the clinical, immunophenotypic, and molecular characteristics of 29 nonhepatosplenic Tcell lymphomas suspected of being gd TCL, and explore new diagnostic markers potentially useful for diagnosis in routinely processed paraffin-embedded material.
MATERIALS AND METHODS

Tissue Samples
A total of 35 lymphomas were collected from the pathology files of the National Cancer Institute (Bethesda, MD), Hospital Clı´nic (Barcelona, Spain), Chi-Mei Medical Center (Tainan, Taiwan), Hospital Henri Mondor (Cre´teil, France), and Hospital Verge de la Cinta (Tortosa, Spain). Cases were classified according to the current WHO classification. 32 Six of the cases had proven expression of the gd receptor by flow cytometry or frozen section immunohistochemistry, and were used in part to assist in the validation of the immunohistochemical studies. An additional 29 cases of mature TCL, suspected of being gd TCL on the basis of absent TCRb chain expression and a cytotoxic phenotype, were studied. Information regarding sites of disease, therapy, and clinical course was obtained. Five patients were previously reported (cases 15, 17 to 20) . 10 This study was approved by the Intramural Research Boards of the participating institutions.
Immunohistochemistry and Hybridization Studies
Immunohistochemical analysis was conducted using a large panel of monoclonal antibodies detecting CD3, CD2, CD4, CD5, CD7, CD8, CD56, CD30, T-cell restricted intracellular antigen-1 (TIA-1), and granzyme B, as previously reported. 3, 19 Detection of the TCRd chain was performed using a primary monoclonal antibody raised against the human TCRd constant region (Human Pan TCRgd1, clone 5A6.E9; Thermo Scientific, IL) (see Supplemental Digital Content online only http:// links.lww.com/PAS/A85). Only membranous staining was considered positive, irrespective of intensity. For TCRb, we used a mouse monoclonal antibody (TCR 1151, clone 8A3; Pierce Endogen, IL). In cases with no detectable expression of either d or b chain and with additional sections available, TCRg chain detection was performed using the monoclonal antibody TCR 1153 (clone g3.20; Thermo Scientific, IL). 31 Epstein-Barr virus (EBV) was detected using in situ hybridization with Epstein-Barr virus encoded small RNA (EBER) probes (INFORM EBER, Benchmark XT; Ventana Medical Systems, Tucson, AZ).
To determine whether the 5A6.E9 anti-TCRd1 antibody could recognize gd T cells with a wide repertoire of TCRd chains in formalin-fixed paraffin embedded cells, we obtained an enriched population of gd T cells from peripheral blood mononuclear cells of healthy donors (see Supplemental Digital Content online only http:// links.lww.com/PAS/A85). After enrichment, the purity of the gd T cells was assessed by flow cytometry. A pellet of these cells was formalin-fixed and embedded in paraffin, and the sections were stained with the 5A6.E9 antiTCRd1 antibody (Supplemental Digital Content Figure 1 http://links.lww.com/PAS/A83, online only). As a control group, we also studied normal tissues (Supplemental Digital Content Figure 2 http://links.lww.com/PAS/A84, online only), 8 cytotoxic TCRb chain-positive TCLs, not otherwise specified, 1 subcutaneous panniculitis-like TCL, and 6 EBV-positive NK/T-cell malignancies. In all of them, the tumor cells were negative for TCRd chain expression, although some reactive cells were easily identified in the reactive background.
TCR Gene Rearrangements
Polymerase chain reaction analysis of the TCRg gene was conducted using the BIOMED2 protocol as described elsewhere. 14, 19, 36 DNA was extracted from formalin-fixed tissues using the QIAamp DNA mini kit (Qiagen, Hilden, Germany). Cases from the National Cancer Institute were characterized for TCRg rearrangement as previously described. 15 
RESULTS
The main clinical and pathologic features are summarized in Tables 1 and 2 respectively. On the basis of review, 8 cases were classified as PCGD-TCL and 6 cases as HSTL. Eight additional cases were proven to be of gd origin, 2 of which had features of enteropathy-associated TCL (EATL), type II, following WHO criteria for enteropathy (villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis). 32 The remaining 6 gd TCLs involved mainly extranodal sites, including 1 intestinal case without features of enteropathy. Thirteen cases were classified as TCL, "TCR silent," and involved mainly extranodal sites. The clinical and pathologic features are detailed below.
PCGD-TCL
Eight cases were classified as PCGD-TCL. This tumor occurred mainly in adults (median age, 46 y; age range, 16 to 63 y). The male to female ratio was 3:5. A mean follow-up of 14 months was recorded (range, 1 to 25 mo). Six patients were treated with multiagent systemic chemotherapy, and 2 cases received additional radiotherapy. One patient was treated with corticosteroids alone. Most patients experienced an aggressive clinical course with extranodal and nodal dissemination. Six patients died as a result of the disease between 1 and 22 months after the initial diagnosis. One patient (case 5) underwent allogeneic bone marrow transplantation and had no evidence of disease 25 months after diagnosis. One patient (case 7) experienced persistence of the disease at the last follow-up.
Histologically, 6 of these tumors were composed of small/medium-sized atypical lymphocytes. In all cases, the tumor involved the subcutis, and in 6 it extended into the dermis. All tumors had an activated cytotoxic phenotype. Six cases were double negative for CD4 and CD8, whereas 2 cases expressed CD8. Expression of CD56 was observed only in 3 of 7 patients. In all cases, gd TCR expression was convincingly demonstrated by positive staining for the TCRd chain. In 2 cases, gd TCR expression was further confirmed by flow cytometry in one case and by immunohistochemistry on frozen sections in a second case.
A clonal TCRg gene rearrangement was observed in 6 cases, whereas 1 case showed a germline configuration of the TCRg gene. EBV infection was observed in 2 cases (cases 6 and 7) in which the strong d chain expression excluded a NK-cell origin (Fig. 1) . In 1 EBV-positive case, TCRg gene rearrangement confirmed a T-cell origin, but polymerase chain reaction studies could not be carried out in the second case.
Hepatosplenic TCL
Six cases were classified as HSTL following the criteria of the WHO classification. No male patient predominance was observed; 2 patients were men while 4 were women. The median age was 44 years (range, 24 to 62 y). Follow-up was available in 4 patients. Two patients achieved complete remission after chemotherapy, which included allogeneic stem-cell transplantation in one patient (case 11) and autologous stem-cell transplantation in the other case (case 12). Median overall survival was 25 months (range, 15 to 35 mo), and 1 patient was still alive 35 months from the initial diagnosis. Case 13 did not receive any adjuvant therapy, and was alive and in remission 32 months after splenectomy. The remaining 2 patients, after initial response to therapy, died as a result of progression of lymphoma.
In all cases, the tumor cells exhibited CD3
-, and CD8 -phenotypes with expression of TIA-1; 2 cases were also positive for granzyme B (Fig. 2) . Staining for TCRd chain was positive in all cases, and expression was confirmed in 2 by flow cytometry. In situ hybridization for EBV was performed in 5 cases, and was negative in all cases. Five cases had TCRg gene rearrangement.
TCLs With Intestinal Involvement
There were 6 male patients, with a median age of 58 years (range, 49 to 72 y). None of them had a history of celiac disease, and 5 patients were Asian and 1 was Hispanic. All patients underwent surgical resection and adjuvant chemotherapy. The median follow-up duration was 14 months. Five patients died of disease within 2 to 34 months.
Tumor cells were small to medium in all cases and extended through the submucosa, with perforation in 5 cases. Histologically, all tumors showed a diffuse monotonous lymphoid infiltrate, as described in the monomorphic or type II variant of EATL. However, features of enteropathy with increased intraepithelial lymphocytes (IELs) in the mucosa adjacent to the tumor were only clearly seen in 2 cases (cases 15 and 16), 1 Asian and 1 Hispanic, both male patients. All tumors expressed CD3, CD7, CD8, CD56, and cytotoxic granule-associated proteins (Fig. 3) , whereas stains for CD4 (6/6), CD5 (6/6), and CD30 (2/3) were negative. Three cases showed unequivocal TCRgd derivation with strong TCRd chain expression (Fig. 3H) , including the 2 cases of EATL, type II. Three cases were negative for both TCRd and TCRb chains. Admixed reactive TCRgd and TCRab tumorinfiltrating T cells were present, confirming the validity of the techniques. In addition, immunohistochemistry for the TCRg chain was performed and the tumor cells also lacked TCRg chain expression. All cases had clonal TCRg gene rearrangement and were EBV negative by in situ hybridization.
Other cd TCLs
Five patients presented with gd T-cell tumors exhibiting strong d chain expression that did not correspond to any of the WHO categories; these were designated as gd TCL, not otherwise specified. There were 2 male and 3 female patients, with a median age of 44 years (range, 29 to 68 y). None of them had cutaneous or hepatosplenic involvement at diagnosis. Two cases had primary nodal involvement (Fig. 4) . The remaining 3 patients showed extranodal disease involving the lung (case 21), orbit (case 22), and tongue (case 24). The 
Gr-B indicates granzyme B; Nd, not done. patients were treated with chemotherapy (cases 21, 23, and 25) or only underwent surgical excision (cases 22 and 24). During follow-up, 1 patient developed skin lesions and liver involvement (case 21). At the time of last followup (median follow-up 17 mo; range, 5 to 48 mo), 2 patients died of disease, whereas 3 patients were in complete remission. All cases exhibited an activated cytotoxic phenotype, with expression of TIA-1 and granzyme B in all tested cases. Three cases were double negative for CD4 and CD8, whereas 2 cases were CD8 positive. CD5 was lost in 5 of 7 tested cases, and all cases were CD56 positive. TCRd expression was confirmed in 2 cases by flow cytometry. A clonal peak for TCRg was observed in all cases. EBV infection was detected in 1 case (case 23), which presented in the lymph node.
Peripheral TCL, TCR Silent
Lack of any form of TCR expression was observed in 13 cases: 3 were classified as TCL with intestinal involvement and are discussed with the other intestinal neoplasms; the remaining 10 cases were grouped as TCL, TCR silent. There was a marked male predominance (8 of 10 were men). The median age of the patients in this category was 50 years, range 22 to 84 years. At initial presentation, 6 cases had cutaneous lesions (cases 27 to 32), 2 cases had features of HSTL (cases 26 and 33), and the remaining cases involved the lymph node and central nervous system (cases 34 and 35, respectively). All but 1 patient was treated with chemotherapy, and in 2 of the 5 patients with available clinical records radiotherapy was added. Mean follow-up was 20 months. Most patients experienced an aggressive clinical course, and 5 patients died with progression of the disease.
The tumor cells were negative for TCRd and TCRb chain expression by immunohistochemistry, although some reactive lymphocytes expressing both TCR receptors were easily identified in the reactive background. In 4 cases with additional available sections, immunohistochemistry for the TCRg chain was performed and the tumor cells also lacked TCRg chain expression. The tumor cells expressed CD3 but not CD4 or CD5. Three cases showed CD8 expression. In all cases, a diagnosis of NK/T-cell lymphoma, nasal type was excluded, either by a monoclonal TCRg gene rearrangement (8 cases) or absence of EBV infection (8 cases). Interestingly, case 26 was originally diagnosed as an ab variant of HSTL (Fig.  5 ). This case was negative for TCRd chain and was positive for TCRb chain by both immunohistochemistry and flow cytometry of the splenectomy specimen. In subsequent studies after splenectomy, an abnormal T-cell population with an identical neoplastic phenotype but lacking TCRb chain expression was demonstrated in the bone marrow and peripheral blood compartments by flow cytometry. A molecular study for TCRg chain gene rearrangement demonstrated a clone of identical size in the spleen, bone marrow, and peripheral blood examined both before and after surgery (Fig. 5) .
DISCUSSION
TCLs of gd cell origin represent a rare form of lymphoma with aggressive behavior and poor outcome. 5, 38 HSTL and PCGD-TCL are recognized in the 2008 WHO classification of lymphoid neoplasms as the 2 main types of TCL that express a gd TCR. 32 In the absence of flow cytometric studies or frozen material, these cases are diagnosed based on clinicopathologic features and "the typical phenotype: CD3 + , CD56 + , CD5
À , CD4 À , CD8 À in the absence of TCRbetta expression." Some cases with uncommon clinical presentations or not fulfilling this phenotype are more difficult to categorize and may not be appreciated as being of gd T-cell origin.
Several studies have described the presence and the distribution of gd TCR's in frozen tissue sections, 17, 20, 22 but their characterization in routinely processed tissues has been less successful. 29, 31 The detection of a gd TCR in formalin-fixed, paraffin-embedded tissues is currently a technological challenge that hampers the diagnosis and understanding of gd T-cell lymphoproliferative disorders. In this study, we have demonstrated the mutually exclusive expression of TCRb and TCRd chains in several types of TCL in routinely processed tissues.
TCRd chain expression was demonstrated in 8 of 14 tumors initially diagnosed as PCGD-TCL and in 6 of 8 HSTLs. Of note, TCRd chain expression was observed in 8 cases of TCRb negative TCL without hepatosplenic or cutaneous involvement at diagnosis. Three of these patients presented with intestinal involvement, 2 of which had features of EATL, type II. The remaining cases had the characteristic phenotype of PCGD-TCL but presented with pulmonary, orbital, nodal, and tongue involvement. In contrast to most gd TCLs, 3 of the non-intestinal cases had an indolent clinical course. This heterogeneity in histologic and clinical features suggests that non-HSTL is not a homogeneous clinical entity. -, bF1 -immunophenotype. In 3 cases, a gd T-cell origin was proven. However, only 2 of them showed intraepithelial lymphocytosis fulfilling the criteria for type II EATL. EATL is defined as an intestinal tumor of IEL with villous atrophy and crypt hyperplasia in the adjacent, non-neoplastic small intestinal mucosa. The monomorphic variant (type II EATL) may occur sporadically, without risk factors for celiac disease. Our 2 EATL type II cases were from patients of Asian and Hispanic ethnicities, in whom celiac disease and EATL have rarely been reported. 10 EATL type II has been suggested to be derived from IELs with a gd phenotype. 13, 21, 28 The fact that the 2 cases of EATL type II in our series had a gd phenotype may support this theory. 1, 9, 37 Notably, 3 additional TCLs with intestinal involvement lacking diagnostic criteria for EATL had similar clinical, cytologic, and immunophenotypic features, but lacked TCRb, TCRd, and TCRg chain expression. Thus, they were defined as TCR silent. Recently, a benign gastrointestinal NK-cell enteropathy has been reported that may closely mimic EATL. 30, 33 The cells of NK-cell enteropathy are CD8 negative and lack TCR expression and TCR gene rearrangement. In contrast, the intestinal TCR silent cases were TCRg clonal and CD8 positive.
We identified a total of 13 TCLs that were negative for both TCRd and TCRb chains. In 7 of these cases, we performed immunostaining for the TCRg chain, which was negative as well. Rare TCL with a lack of TCR expression had been previously recognized in cases studied by frozensection immunohistochemistry, and had been designated as TCR silent TCL. 20 Six of our TCR silent TCL cases had clinical and pathologic features resembling PCGD-TCL, whereas 2 mimicked a HSTL. As noted above, 3 presented with intestinal disease. We believe it is most likely that the TCR silent phenotype represents a common phenomenon of "TCR instability" in different tumor types, rather than representing a distinct clinicopathologic entity. In favor of this hypothesis was the observation of a TCR ab HSTL that evolved to a TCR silent phenotype with an identical TCR gene rearrangement pattern after splenectomy. A similar phenomenon had been reported in gd HSTL associated with histologic progression and in EATLs evolving from refractory celiac disease. 18, 34 Thus, the lack of TCR expression may represent a phenotypic aberration in TCL, usually encountered at the time of progression. This finding indicates further that the lack of TCRb chain expression cannot be used to infer a gd T-cell origin with certainty.
Although most of our cases were unrelated to EBV infection, EBER was detected in the neoplastic cells of 3 cases of gd TCL. This phenomenon has been observed previously in rare examples of HSTL and non-HSTL. 2, 5 It is difficult to resolve whether such cases should be classified as NK/T-cell lymphoma or gd TCL, EBV positive as even gene expression profiles may be similar in both entities. 25 The absence of angiocentricity, the strong TCRd chain expression, and the evidence of a clonal TCR gene rearrangement favored a gd T-cell origin. Moreover, EBV positivity is more common in individuals of Asian origin and Native American descent in Central and South America, and 1 of our cases was diagnosed in a patient from Mexico.
In summary, our observations indicate that the spectrum of gd-derived TCL is broader than previously appreciated. Although HSTL and PCGD-TCL are recognized in the 2008 WHO classification, we identified a number of other gd TCLs presenting in other mainly extranodal or more rarely nodal sites. The heterogeneity of these cases suggests that non-HSTL gd TCL is not a single entity. It also seems that a high proportion of type II EATL is derived from gd T cells. However, there is still a subset of TCLs with intestinal involvement that exhibits either a gd-TCR or TCR silent phenotype and lacks features of enteropathy. Finally, the recognition of a group of silent TCL's indicates that a lack of TCRb expression cannot be used to predict a gd T-cell origin. The addition of genetic or genomic data in the future may help to resolve the apparent diversity in these heterogeneous and aggressive neoplasms.
